XCUR / Exicure, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Exicure, Inc. Reports Second Quarter 2025 Financial Results

Exhibit 99.1 Exicure, Inc. Reports Second Quarter 2025 Financial Results REDWOOD CITY, CA — August 8, 2025 — Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended June 30, 2025. Second Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $7.9 million as of June 30, 2025, as compared to $12.5 million as of December

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 EXICURE, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39011 EXI

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Exhibit 99.1 Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements Redwood City, CA (BUSINESS WIRE) — August 4, 2025 — Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR) a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that, as of July 1, 2025, the Company regained compliance with the periodic filing requireme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 EXICURE, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Numbe

Exicure, Inc. 5,164,595 Shares of Common Stock Offered by the Selling Stockholders

Filed Pursuant to Rule 424(b)(3) Registration No. 333-288658 PROSPECTUS Exicure, Inc. 5,164,595 Shares of Common Stock Offered by the Selling Stockholders This Prospectus (this “Prospectus”) relates to the proposed resale or other disposition by the selling stockholders identified herein (the “Selling Stockholders”) of up to 5,164,595 shares of our common stock of Exicure, Inc. (the “Company,” “Ex

Exicure, Inc. 400 Seaport Court, Suite 102 Redwood City, California 94063 July 18, 2025

Exicure, Inc. 400 Seaport Court, Suite 102 Redwood City, California 94063 July 18, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jason Drory Re: Exicure, Inc. Registration Statement on Form S-1 File No. 333-288658 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act

As filed with the Securities and Exchange Commission on July 11, 2025

As filed with the Securities and Exchange Commission on July 11, 2025 Registration No.

Subsidiaries of Exicure, Inc.

Exhibit 21.1 Subsidiaries of Exicure, Inc. Name: Jurisdiction of Organization: Exicure Operating Company Delaware GPCR Therapeutics USA Inc. California KC Creation Co., Ltd. South Korea

Employment Agreement, dated December 20, 2024, between the Company and Andy Yoo

Exhibit 10.32 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), by and among Exicure, Inc. (the “Company”) and Andy Yoo (“You” or “Your”) (the Company and You each a “Party”, and collectively the “Parties”), is entered into and effective as of December 20, 2024 (the “Effective Date”).1 WHEREAS, the Company desires to employ You as its Chief Executive Officer and You desire to accep

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees t

Employment Agreement, dated December 20, 2024, between the Company and Seung Ik Baik

Exhibit 10.33 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), by and among Exicure, Inc. (the “Company”) and Seung Ik Baik (“You” or “Your”) (the Company and You each a “Party,” and collectively the “Parties”), is entered into and effective as of December 20, 2024 (the “Effective Date”).1 WHEREAS, the Company desires to employ You as its Chief Financial Officer and You desire to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 EXICURE, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Number

Share Purchase Agreement, dated January 19, 2025, between the Company and GPCR

Exhibit 10.1 Executed Version SHARE PURCHASE AGREEMENT between GPCR THERAPEUTICS, INC. and EXICURE, INC. dated as of January 19, 2025 TABLE OF CONTENTS ARTICLE I PURCHASE AND SALE 5 Section 1.01 Purchase and Sale 5 Section 1.02 Purchase Price 5 Section 1.03 Withholding Taxes 5 ARTICLE II CLOSING 6 Section 2.01 Closing 6 Section 2.02 Seller Closing Deliverables 6 Section 2.03 Buyer's Deliveries 6 A

License and Collaboration Agreement, dated January 19, 2025, between the Company and GPCR

Exhibit 10.2 Executed Version LICENSE AND COLLABORATION AGREEMENT THIS LICENSE AND COLLABORATION AGREEMENT (“Agreement”) is entered into as of January 19, 2025 (the “Effective Date”) by and between A. GPCR Therapeutics, Inc., a Korean corporation with its principal offices at Nakseongdae R&D Center, 38, Nakseongdae-ro, Gwanak-gu, Seoul 08790 Korea (“GPCR”) and B. Exicure, Inc., an Illinois corpora

Consulting Agreement by and between the Company and Alta Companies Ltd., dated February 27, 2025

Exhibit 10.5 Executed Version February 1, 2025 Mr. Andy Yoo Exicure, Inc. 2430 N. Halsted St. Chicago, IL 60614 USA Dear Mr. Yoo: This agreement summarizes the terms and conditions upon which Alta Companies Ltd. (“ALTA”) will provide Paul Kang as a Senior Advisor and assist Exicure, Inc. and affiliates (the “COMPANY”) with respect to corporate development, capital raising, and mergers/acquisitions

Exicure, Inc. Reports First Quarter 2025 Financial Results

Exhibit 99.1 Exicure, Inc. Reports First Quarter 2025 Financial Results REDWOOD CITY, CA — June 27, 2025 — Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended March 31, 2025. First Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39011 EX

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Number)

First Amendment to Employment Agreement between Exicure, Inc. and Andy Yoo, dated as of April 1, 2025

Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is effective as of the 1st day of April 2025 (the “Effective Date”), by and between Andy Yoo (“You” or “Your”) and Exicure, Inc. (the “Company”). Each of You and the Company are herein referred to as a “Party,” and collectively, the “Parties.” RECITALS WHEREAS, the Company and You e

First Amendment to Employment Agreement between Exicure, Inc. and Seung Ik Baik, dated as of April 1, 2025

Exhibit 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is effective as of the 1st day of April 2025 (the “Effective Date”), by and between Seung (Louis) Ik Baik (“You” or “Your”) and Exicure, Inc. (the “Company”). Each of You and the Company are herein referred to as a “Party,” and collectively, the “Parties.” RECITALS WHEREAS, the Comp

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exhibit 99.1 Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q Redwood City, CA (BUSINESS WIRE) — May 28, 2025 — Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2025 notifying the Company that, as a result of the Company’s failure to timely file its Qu

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 (May 21, 2025) EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39011 CUSIP NUMBER 30205M200

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39011 CUSIP NUMBER 30205M200 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR ☐ For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 (April 30, 2025) EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commiss

Convertible Bond Agreement, dated April 30, 2025, between KC Creation Co. Ltd. and Exicure, Inc.

Exhibit 10.1 The 1st Convertible Bond Agreement KC Creation Co Ltd 1st Bearer-type Non-guaranteed Private Placement Convertible Bonds Agreement Date of Acquisition Contract : 2025. 04. 30. Payment and Issuance Date: 2025. 04. 30. The 1st Convertible Bond Agreement Convertible Bond Agreement This convertible bond acquisition agreement (hereinafter referred to as the "This Agreement") was entered in

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Numbe

Letter from Marcum dated April 14, 2025

Exhibit 16.1 April 14, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Exicure, Inc. under Item 4.01 of its Form 8-K dated April 14, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Exicure, Inc. contained therein. Very tr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39011

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Numbe

Exicure, Inc. Reports Full Year 2024 Financial Results

Exhibit 99.1 Exicure, Inc. Reports Full Year 2024 Financial Results CHICAGO, IL — March 18, 2025 — Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Exicure, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Registration Rights Agreement, dated as of February 14, 2025, by and among Exicure, Inc. and Shin Chang Partners and RMS0718 Co., Ltd.

Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February 14, 2025, by and among Exicure, Inc., a Delaware corporation (the “Company”), and each purchasers identified on Schedule 1 hereto or an Affiliate thereof (each, including its successors and assigns, a “Purchaser” and together, the “Purchasers”),

Common Stock Purchase Agreement, dated as of February 14, 2025, by and among Exicure, Inc. and Shin Chang Partners and RMS0718 Co., Ltd.

Exhibit 10.1 Execution Version COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the “Agreement”), dated as of February 14, 2025, by and among Exicure, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Schedule 1 hereto or an Affiliate thereof (each, including its successors and assigns, a “Purchaser” and together, the “Purchasers”). Capitalized ter

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Nu

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File N

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exhibit 99.1 Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. CHICAGO, IL. – January 23, 2025 - Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that on January 19, 2025, Exicure Inc. (“the Company”) entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation (“GPCR”), pursuant to which the Company acquired from GPCR all of

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2025 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Num

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.

Exhibit 99.1 Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc. CHICAGO, IL. – January 22, 2025 - Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that on January 19, 2025, Exicure Inc. (“the Company”) entered into a Share Purchase Agreement with GPCR Therapeutics, Inc., a Korean corporation (“GPCR”), pursuant to which the Company acquired from GPCR all

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2025 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Nu

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

EX-99.1 2 ex991pressrelease122124.htm EX-99.1 Exhibit 99.1 Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes CHICAGO, IL. – December 21, 2024 - Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that in connection with the change of control transaction approved by the stockholders at the Special Me

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Nu

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exhibit 99.1 Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes CHICAGO, IL. – December 20, 2024 - Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders on December 17, 2024

EXICURE, INC. UNAUDITED PROFORMA CONSOLIDATED BALANCE SHEETS (in thousands)

Exhibit 99.1 EXICURE, INC. UNAUDITED PROFORMA CONSOLIDATED BALANCE SHEETS (in thousands) October 31, 2024 (Unaudited) December 17, 2024 (Pro Forma) ASSETS Current assets: Cash and cash equivalents $ 597 $ 3,574 Other receivable 800 921 Prepaid expenses and other current assets 929 889 Total current assets 2,326 5,384 Property and equipment, net 31 29 Right-of-use asset 5,858 5,790 Other noncurrent

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Nu

Common Stock Purchase Agreement, dated December 9, 2024, by and between Exicure, Inc. and SangSangIn Investment & Securities Co., Ltd.

Exhibit 10.1 Execution Version COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the “Agreement”), dated as of December 9, 2024, by and among Exicure, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Schedule 1 hereto or an Affiliate thereof (each, including its successors and assigns, a “Purchaser” and together, the “Purchasers”). Capitalized term

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Num

Form of Registration Rights Agreement by and between Exicure, Inc. and SangSangIn Investment & Securities Co., Ltd.

Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of December 9, 2024, by and among Exicure, Inc., a Delaware corporation (the “Company”), and each purchasers identified on Schedule 1 hereto or an Affiliate thereof (each, including its successors and assigns, a “Purchaser” and together, the “Purchasers”),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

XCUR / Exicure, Inc. / HiTron Systems Inc. - SC 13D Activist Investment

SC 13D 1 d882574dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Exicure, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M309 (CUSIP Number) Andy Yoo Chief Executive Officer HiTron Systems Inc. 99-13 Masan-Gil, Miyang-Myeon Anseong-s

25th Bearer-type Non-guaranteed Private Placement Convertible Bonds Agreement, dated September 6, 2024 by and between HiTron Systems Inc. and Widwin Investment Fund No. 72.

EX-99.4 2 d882574dex994.htm EX-99.4 Exhibit 99.4 The 25th Convertible Bond Agreement HiTron Systems Inc 25th Bearer-type Non-guaranteed Private Placement Convertible Bonds Agreement Date of Acquisition Contract : 2024. 09. 06. Payment and Issuance Date: 2024. 09. 19. page 1 / 26 The 25th Convertible Bond Agreement Convertible Bond Agreement This convertible bond acquisition agreement (hereinafter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 Exicure, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: þ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 EXICURE, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Nu

Form of Registration Rights Agreement by and between Exicure, Inc. and HiTron Systems, Inc.

Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of November 6, 2024, by and among Exicure, Inc., a Delaware corporation (the “Company”), and each purchasers identified on Schedule 1 hereto (each, including its successors and assigns, a “Purchaser” and together, the “Purchasers”), and shall become effecti

Common Stock Purchase Agreement, dated November 6, 2024, by and between Exicure, Inc. and HiTron Systems, Inc.

Exhibit 10.1 Execution Version COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the “Agreement”), dated as of November 6, 2024, by and among Exicure, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Schedule 1 hereto (each, including its successors and assigns, a “Purchaser” and together, the “Purchasers”). Capitalized terms used herein but not ot

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exhibit 99.1 Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results CHICAGO, IL — November 14, 2024 — Exicure, Inc. (Nasdaq: XCUR, the "Company") has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In Se

Common Stock Purchase Agreement, dated November 13, 2024, by and between Exicure, Inc. and HiTron Systems, Inc.

Exhibit 10.3 Execution Version COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the “Agreement”), dated as of November [13], 2024, by and among Exicure, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Schedule 1 hereto (each, including its successors and assigns, a “Purchaser” and together, the “Purchasers”). Capitalized terms used herein but not

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3901

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Nu

Debt for Equity Exchange Agreement

DEBT-FOR-EQUITY EXCHANGE AGREEMENT This DEBT-FOR-EQUITY EXCHANGE AGREEMENT (this “Agreement”), dated as of September 12, 2024 (the “Effective Date”), is made by and between Exicure, Inc.

Asset Purchase Agreement by and between Flashpoint Therapeutics, Inc. and Exicure, Inc. dated as of September 27, 2024.

Exhibit 10.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (the “Agreement”) is entered into and made effective as of September 27, 2024 (the “Effective Date”), by and between Exicure, Inc., a corporation organized under the laws of Delaware (“Exicure”) and Flashpoint Therapeutics, Inc., a corporation organized under the laws of Delaware (“Flashpoint”). Exicure and Flashpoint are also ref

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 (September 26,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 (September 26, 2024) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporatio

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File N

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Exhibit 99.1 Exicure, Inc. Receives Extension from Nasdaq Hearings Panel CHICAGO, IL. — September 18, 2024 — Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to continue the Company’s listing subject to the Company evidencing compliance with all applicable

XCUR / Exicure, Inc. / CBI USA, Inc. - SC 13D/A Activist Investment

SC 13D/A 1 d825676dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 14) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M309 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. and DGP Co., Ltd. c/o Baker & Hostet

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File N

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Numb

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Exhibit 99.1 Exicure, Inc. Announces 1-for-5 Reverse Stock Split CHICAGO, IL. – August 26, 2024 - Exicure, Inc. (Nasdaq: XCUR, “the Company”), today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its c

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Exicure, Inc., effective August 27, 2024

Exhibit 3.1 Execution Version CERTIFICATE OF AMENDMENT Exicure, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, as amended (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is Exicure, Inc. The Certificate of Incorporation of the Corporation was originally filed with the Secretary

###

Exhibit 99.1 Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting CHICAGO, IL — August 19, 2024 — Exicure, Inc. (Nasdaq: XCUR, the "Company"), announced today that its Special Meeting of Stockholders (the "Special Meeting"), initially scheduled for August 15, 2024 and adjourned and reconvened on August 19, 2024, has been adjourned again f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 EXICURE, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Numb

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exhibit 99.1 Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting CHICAGO, IL — August 15, 2024 — Exicure, Inc. (Nasdaq: XCUR, the "Company"), announced today that its Special Meeting of Stockholders (the "Special Meeting") scheduled for and convened on August 15, 2024 has been adjourned for the purpose of soliciting additional votes with respect to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 EXICURE, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39011 EXI

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exhibit 99.1 Exicure, Inc. Reports Second Quarter 2024 Financial Results CHICAGO, IL — August 13, 2024 — Exicure, Inc. (Nasdaq: XCUR, the "Company"), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of pre

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Numb

Assignment and Waiver Agreement

EX-99.2 3 d845592dex992.htm EX-99.2 Exhibit 2 Assignment and Waiver Agreement OVERDIGMK CO., LTD. (the “Purchaser”) agrees to DGP CO., LTD. (the “Seller”) as follows: ————————————————————— A G R E E M E N T ——————————————————————- (1) Upon Seller’s request, Purchaser shall assign all of its rights and obligations from the Stock Purchase Agreement dated February 28, 2024 (the “Agreement”) to a thir

Second Amendment

EX-99.1 2 d845592dex991.htm EX-99.1 Exhibit 1 Second Amendment 1. Underlying Agreement : Stock Purchase Agreement (the “Original Agreement”) 2. Date of Original Agreement : February 29, 2024 3. Purpose of Original Agreement : Agreement to sell the shares issued by Exicure, Inc. [NASDAQ: XCUR] (the “Company”) owned by DGP Co., Ltd. (the “Seller”) 4. Date of First Amendment : June 28, 2024 5. Purpos

XCUR / Exicure, Inc. / CBI USA, Inc. - SC 13D/A Activist Investment

SC 13D/A 1 d845592dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 13) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M200 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. and DGP Co., Ltd. c/o Baker & Hostet

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Exhibit 99.1 Exicure, Inc. Receives Positive Listing Determination from Nasdaq CHICAGO, IL. — August 1, 2024 — Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on July 31, 2024, the Company received formal notice that the Nasdaq Hearings Panel (“Panel”) has determined to continue the Company’s listing subject to the Company evidencing compliance with all applicable c

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 (July 31, 2024) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: þ Preliminary Proxy S

- A G R E E M E N T -

EX-99.2 3 d842225dex992.htm EX-99.2 Exhibit 2 Amendment CBI USA, INC. (“CBI USA”) and DGP CO., LTD. (“DGP”) have entered into this Amendment (this “Amendment”) to amend the Stock Loan Agreement dated February 29, 2024 (the “Original Agreement”) and agree as follows: - A G R E E M E N T - 1. Lender : CBI USA 2. Borrower : DGP 2. Shares : 340,000 shares of common stock of EXICURE, INC. (“XCUR”) owne

2024. 06. 28. (“Seller”) Address : 23, Geurintekeu-ro, Yeonggwang-eup, Yeonggwang-gun, Jeollanam-do, Republic of Korea 57024 Company Name : DGP CO., LTD. Signed By : Kyungwon Oh, CEO (DGP corporate seal) (“Purchaser”) Address : 362-37, Toseong-ro, Hy

EX-99.1 2 d842225dex991.htm EX-99.1 Exhibit 1 Amendment 1. Underlying Agreement : Stock Purchase Agreement (the “Original Agreement”) 2. Date of Original Agreement : February 29, 2024 3. Purpose of Original Agreement : Agreement to sell the shares issued by Exicure, Inc. [NASDAQ: XCUR] (the “Company”) owned by DGP Co., Ltd. (the “Seller”) DGP CO., LTD. (the “Seller”) and OVERDIGMK CO., LTD. (the “

XCUR / Exicure, Inc. / CBI USA, Inc. - SC 13D/A Activist Investment

SC 13D/A 1 d842225dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 12) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M200 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. and DGP Co., Ltd. c/o Baker & Hostet

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Exicure, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Number

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 (June 20, 2024) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39011 EX

Exicure, Inc. Reports First Quarter 2024 Financial Results

Exhibit 99.1 Exicure, Inc. Reports First Quarter 2024 Financial Results CHICAGO, IL — June 17, 2024 — Exicure, Inc. (Nasdaq: XCUR, the "Company"), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of precli

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy S

Convertible Bond Subscription Agreement, dated May 16, 2023, among Cyworld Z Co., Ltd. and Exicure, Inc.

Exhibit 10.5 Cyworld Z Co., Ltd. 14th Bearer’s Non-Guaranteed Private Placement Convertible Bonds With Coupons Convertible Bond Subscription Agreement Total Issue Amount : USD 1,000,000 Subscription Agreement Execution Date: [5/16], 2023 Payment Date and Issue Date: [5/16], 2023 1 Convertible Bond Subscription Agreement This Convertible Bond Subscription Agreement (the “Agreement”) is made and ent

Separation and Release Agreement, dated May 27, 2023, among Exicure, Inc. and Sarah Longoria.

Exhibit 10.6 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) by and between Exicure, Inc. (the “Company”) and Sarah Longoria (“You” or “Your”) (the Company and You collectively referred to as the “Parties”), is entered into and effective as of May 26, 2023 (the “Effective Date”). WHEREAS, You have been employed by the Company on an at-will basis; WHEREAS, t

Employment Agreement, dated April 27, 2023, among Exicure, Inc. and Jung S. Kim.

Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), by and among Exicure, Inc. (the “Company”) and Jung S. Kim (“You” or “Your”) (the Company and You each a “Party”, and collectively the “Parties”), is entered into and effective as of April 27, 2023 (the “Effective Date”).1 WHEREAS, the Company desires to employ You as its Chief Executive Officer, and You desire to accep

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 2

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 2 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num

Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 (June 3, 2024) EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commissi

Exicure, Inc. Reports Full Year 2023 Financial Results

Exhibit 99.1 Exicure, Inc. Reports Full Year 2023 Financial Results CHICAGO, IL — June 6, 2024 — Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and

Compensation Recoupment Policy

Exhibit 97 Exicure, Inc. (A Delaware Corporation) Action By Unanimous Written Consent In Lieu Of Meeting Of Board Of Directors December 1, 2023 Pursuant to Section 141(f) of the General Corporation Law of the State of Delaware (the “DGCL”) and the Amended and Restated Bylaws (the “Bylaws”) of Exicure, Inc., a Delaware corporation (the “Company”), the undersigned, being all of the members of the Bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 2

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 2 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu

Convertible Bond Subscription Agreement, dated May 3, 2023, among Cyworld Z Co., Ltd. and Exicure, Inc.

Exhibit 10.4 Cyworld Z Co., Ltd. 13th Bearer’s Non-Guaranteed Private Placement Convertible Bonds With Coupons Convertible Bond Subscription Agreement Total Issue Amount : USD 1,000,000 Subscription Agreement Execution Date: [5/03], 2023 Payment Date and Issue Date: [5/03], 2023 1 Convertible Bond Subscription Agreement This Convertible Bond Subscription Agreement (the “Agreement”) is made and ent

Amended and Restated Employment Agreement, dated May 24, 2023, among Exicure, Inc. and Joshua Miller.

Exhibit 10.7 Amended and Restated Employment Agreement This Employment Agreement (the “Agreement”) between Exicure, Inc., a Delaware corporation (the “Company”), and Joshua Miller (“Executive”) (each of Executive and the Company, a “Party,” and collectively, the “Parties”), is entered into as of May 9, 2023. Whereas, Executive and the Company are parties to that certain Employment Agreement, dated

Separation and Release Agreement, dated April 26, 2023, among Exicure, Inc. and Elias Papadimas.

Exhibit 10.3 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) by and between Exicure, Inc. (the “Company”) and Elias Papadimas (“You” or “Your”) (the Company and You collectively referred to as the “Parties”), is entered into and effective as of April 26, 2023 (the “Effective Date”). WHEREAS, You have been employed by the Company on an at-will basis; WHEREAS

Retention Agreement, dated May 24, 2023, among Exicure, Inc. and Joshua Miller.

Exhibit 10.3 May 5, 2023 Joshua Miller Re: Retention Agreement Dear Josh: Thank you for all of your contributions to Exicure, Inc. (the “Company”). Your role is key to our success and we are excited to offer you the retention award described below pursuant to the terms and conditions set forth in this agreement (this “Retention Agreement”). This Retention Agreement will be effective as of May 5, 2

Separation and Release Agreement, dated April 26, 2023, among Exicure, Inc. and Matthias Schroff.

Exhibit 10.2 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) by and between Exicure, Inc. (the “Company”) and Matthias Schroff (“You” or “Your”) (the Company and You collectively referred to as the “Parties”), is entered into and effective as of April 26, 2023 (the “Effective Date”). WHEREAS, You have been employed by the Company on an at-will basis; WHEREA

First Amendment to the Separation and Release Agreement of Matthias Schroff, dated June 12, 2023, among Exicure, Inc. and Matthias Schroff.

Exhibit 10.9 FIRST AMENDMENT TO THE SEPARATION & RELEASE AGREEMENT OF MATTHIAS SCHROFF This First Amendment To The Separation & Release Agreement Of Matthias Schroff (the “Amendment”) is effective as of the 12th day of June, 2023 (the “Effective Date”), by and between Matthias Schroff (the former “Executive”) and EXICURE, INC. (the “Company”) (each of the former Executive and the Company, a “Party

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 (May 21, 2024) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commissi

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

Exhibit 99.1 Exicure, Inc. Received Nasdaq Notice of a Delisting Determination CHICAGO, IL. — May 23, 2024 — Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The Staff Delisting Determination notified t

Separation and Release Agreement, dated April 26, 2023, among Exicure, Inc. and Matthias Schroff.

Exhibit 10.2 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) by and between Exicure, Inc. (the “Company”) and Matthias Schroff (“You” or “Your”) (the Company and You collectively referred to as the “Parties”), is entered into and effective as of April 26, 2023 (the “Effective Date”). WHEREAS, You have been employed by the Company on an at-will basis; WHEREA

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Number)

Employment Agreement, dated April 27, 2023, among Exicure, Inc. and Jung S. Kim.

Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), by and among Exicure, Inc. (the “Company”) and Jung S. Kim (“You” or “Your”) (the Company and You each a “Party”, and collectively the “Parties”), is entered into and effective as of April 27, 2023 (the “Effective Date”).1 WHEREAS, the Company desires to employ You as its Chief Executive Officer, and You desire to accep

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu

Amended and Restated Employment Agreement, dated May 24, 2023, among Exicure, Inc. and Joshua Miller.

Exhibit 10.7 Amended and Restated Employment Agreement This Employment Agreement (the “Agreement”) between Exicure, Inc., a Delaware corporation (the “Company”), and Joshua Miller (“Executive”) (each of Executive and the Company, a “Party,” and collectively, the “Parties”), is entered into as of May 9, 2023. Whereas, Executive and the Company are parties to that certain Employment Agreement, dated

Convertible Bond Subscription Agreement, dated May 16, 2023, among Cyworld Z Co., Ltd. and Exicure, Inc.

Exhibit 10.5 Cyworld Z Co., Ltd. 14th Bearer’s Non-Guaranteed Private Placement Convertible Bonds With Coupons Convertible Bond Subscription Agreement Total Issue Amount : USD 1,000,000 Subscription Agreement Execution Date: [5/16], 2023 Payment Date and Issue Date: [5/16], 2023 1 Convertible Bond Subscription Agreement This Convertible Bond Subscription Agreement (the “Agreement”) is made and ent

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3901

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num

Retention Agreement, dated May 24, 2023, among Exicure, Inc. and Joshua Miller.

Exhibit 10.3 May 5, 2023 Joshua Miller Re: Retention Agreement Dear Josh: Thank you for all of your contributions to Exicure, Inc. (the “Company”). Your role is key to our success and we are excited to offer you the retention award described below pursuant to the terms and conditions set forth in this agreement (this “Retention Agreement”). This Retention Agreement will be effective as of May 5, 2

First Amendment to the Separation and Release Agreement of Matthias Schroff, dated June 12, 2023, among Exicure, Inc. and Matthias Schroff.

Exhibit 10.9 FIRST AMENDMENT TO THE SEPARATION & RELEASE AGREEMENT OF MATTHIAS SCHROFF This First Amendment To The Separation & Release Agreement Of Matthias Schroff (the “Amendment”) is effective as of the 12th day of June, 2023 (the “Effective Date”), by and between Matthias Schroff (the former “Executive”) and EXICURE, INC. (the “Company”) (each of the former Executive and the Company, a “Party

Exicure, Inc. Reports Third Quarter 2023 Financial Results

Exhibit 99.1 Exicure, Inc. Reports Third Quarter 2023 Financial Results CHICAGO, IL — May 16, 2024 — Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities

Convertible Bond Subscription Agreement, dated May 3, 2023, among Cyworld Z Co., Ltd. and Exicure, Inc.

Exhibit 10.4 Cyworld Z Co., Ltd. 13th Bearer’s Non-Guaranteed Private Placement Convertible Bonds With Coupons Convertible Bond Subscription Agreement Total Issue Amount : USD 1,000,000 Subscription Agreement Execution Date: [5/03], 2023 Payment Date and Issue Date: [5/03], 2023 1 Convertible Bond Subscription Agreement This Convertible Bond Subscription Agreement (the “Agreement”) is made and ent

Employment Agreement, dated Aug. 28, 2023, among Exicure, Inc. and Jiyoung Hwang

Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), by and among Exicure, Inc. (the “Company”) and Jiyoung Hwang (“You” or “Your”) (the Company and You each a “Party,” and collectively the “Parties”), is entered into and effective as of August 28, 2023 (the “Effective Date”).1 WHEREAS, the Company desires to employ You as its Chief Financial Officer and You desire to acc

Separation and Release Agreement, dated May 27, 2023, among Exicure, Inc. and Sarah Longoria.

Exhibit 10.6 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) by and between Exicure, Inc. (the “Company”) and Sarah Longoria (“You” or “Your”) (the Company and You collectively referred to as the “Parties”), is entered into and effective as of May 26, 2023 (the “Effective Date”). WHEREAS, You have been employed by the Company on an at-will basis; WHEREAS, t

Employment Agreement, dated Aug. 28, 2023, among Exicure, Inc. and Paul Kang

Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), by and among Exicure, Inc. (the “Company”) and Paul Kang (“You” or “Your”) (the Company and You each a “Party”, and collectively the “Parties”), is entered into and effective as of August 28, 2023 (the “Effective Date”).1 WHEREAS, the Company desires to employ You as its Chief Executive Officer and You desire to accept

Separation and Release Agreement, dated April 26, 2023, among Exicure, Inc. and Elias Papadimas.

Exhibit 10.3 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) by and between Exicure, Inc. (the “Company”) and Elias Papadimas (“You” or “Your”) (the Company and You collectively referred to as the “Parties”), is entered into and effective as of April 26, 2023 (the “Effective Date”). WHEREAS, You have been employed by the Company on an at-will basis; WHEREAS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39011 CUSIP NUMBER 30205M200

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39011 CUSIP NUMBER 30205M200 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR ☐ For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 (April 17, 2024) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Comm

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Exhibit 99.1 Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K CHICAGO, IL. — April 22, 2024 — Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39011 CUSIP NUMBER 30205M200

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39011 CUSIP NUMBER 30205M200 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR ☐ For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.

Stock Loan Agreement between the Reporting Persons*

EX-99.2 3 d799381dex992.htm EX-99.2 Exhibit 2 Stock Loan Agreement CBI USA, INC. (“CBI USA”) and DGP CO., LTD. (“DGP”) have entered into this Stock Loan Agreement (the “Agreement”) and agree as follows: - A G R E E M E N T - 1. Lender : CBI USA 2. Borrower : DGP 2. Shares : 340,000 shares of common stock of EXICURE, INC. (“XCUR”) owned by CBI USA 3. Interest Rate : 4.6 % per annum (The interest sh

XCUR / Exicure, Inc. / CBI USA, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 11) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M200 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. and DGP Co., Ltd. c/o Baker & Hostetler LLP One North Wacker Drive

Stock Purchase Agreement of DGP*

EX-99.1 2 d799381dex991.htm EX-99.1 Exhibit 1 Stock Purchase Agreement Article 1 (Purpose) This Stock Purchase Agreement (the “Agreement”) is made between DGP Co., Ltd. (the “Seller”) and OverdigmK Co., Ltd. (the “Purchaser”) to clearly define the trust between the two parties in connection with the sale of the shares issued by Exicure, Inc. [NASDAQ: XCUR] (the “Company”) owned by the Seller to th

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Exhibit 99.1 Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis CHICAGO, IL. — February 5, 2024 — Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, annou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 (February 5, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 (February 5, 2024) EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 (January 11, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 (January 11, 2024) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 (November 28, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation)

Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 (November 22, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation)

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exhibit 99.1 Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q CHICAGO, IL. — November 28, 2023 — Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on November 22, 2023 notifying the Company that, as a result of the Company’s failure to timely file its Quarterly Re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39011 CUSIP NUMBER 30205M200

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39011 CUSIP NUMBER 30205M200 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR ☐ For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2023 (October 3, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Co

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 (September 26, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporatio

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2023 (August 18, 2023)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2023 (August 18, 2023) EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Co

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Exhibit 99.1 Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors CHICAGO, IL. — August 23, 2023 — Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of August 21, 2023, Paul Kang, a Class III director

First Amendment to the Separation and Release Agreement of Matthias Schroff, dated June 12, 2023, among Exicure, Inc. and Matthias Schroff.

Exhibit 10.9 FIRST AMENDMENT TO THE SEPARATION & RELEASE AGREEMENT OF MATTHIAS SCHROFF This First Amendment To The Separation & Release Agreement Of Matthias Schroff (the “Amendment”) is effective as of the 12th day of June, 2023 (the “Effective Date”), by and between Matthias Schroff (the former “Executive”) and EXICURE, INC. (the “Company”) (each of the former Executive and the Company, a “Party

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Numb

Retention Agreement, dated May 24, 2023, among Exicure, Inc. and Joshua Miller.

Exhibit 10.8 May 5, 2023 Joshua Miller Re: Retention Agreement Dear Josh: Thank you for all of your contributions to Exicure, Inc. (the “Company”). Your role is key to our success and we are excited to offer you the retention award described below pursuant to the terms and conditions set forth in this agreement (this “Retention Agreement”). This Retention Agreement will be effective as of May 5, 2

Separation and Release Agreement, dated April 26, 2023, among Exicure, Inc. and Elias Papadimas.

Exhibit 10.3 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) by and between Exicure, Inc. (the “Company”) and Elias Papadimas (“You” or “Your”) (the Company and You collectively referred to as the “Parties”), is entered into and effective as of April 26, 2023 (the “Effective Date”). WHEREAS, You have been employed by the Company on an at-will basis; WHEREAS

Amended and Restated Employment Agreement, dated May 24, 2023, among Exicure, Inc. and Joshua Miller.

Exhibit 10.7 Amended and Restated Employment Agreement This Employment Agreement (the “Agreement”) between Exicure, Inc., a Delaware corporation (the “Company”), and Joshua Miller (“Executive”) (each of Executive and the Company, a “Party,” and collectively, the “Parties”), is entered into as of May 9, 2023. Whereas, Executive and the Company are parties to that certain Employment Agreement, dated

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Exhibit 99.1 Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update CHICAGO, IL. — August 11, 2023 — Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, s

Convertible Bond Subscription Agreement, dated May 16, 2023, among Cyworld Z Co., Ltd. and Exicure, Inc.

Exhibit 10.5 Cyworld Z Co., Ltd. 14th Bearer’s Non-Guaranteed Private Placement Convertible Bonds With Coupons Convertible Bond Subscription Agreement Total Issue Amount : USD 1,000,000 Subscription Agreement Execution Date: [5/16], 2023 Payment Date and Issue Date: [5/16], 2023 1 Convertible Bond Subscription Agreement This Convertible Bond Subscription Agreement (the “Agreement”) is made and ent

Separation and Release Agreement, dated April 26, 2023, among Exicure, Inc. and Matthias Schroff.

Exhibit 10.2 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) by and between Exicure, Inc. (the “Company”) and Matthias Schroff (“You” or “Your”) (the Company and You collectively referred to as the “Parties”), is entered into and effective as of April 26, 2023 (the “Effective Date”). WHEREAS, You have been employed by the Company on an at-will basis; WHEREA

Employment Agreement, dated April 27, 2023, among Exicure, Inc. and Jung S. Kim.

Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), by and among Exicure, Inc. (the “Company”) and Jung S. Kim (“You” or “Your”) (the Company and You each a “Party”, and collectively the “Parties”), is entered into and effective as of April 27, 2023 (the “Effective Date”).1 WHEREAS, the Company desires to employ You as its Chief Executive Officer, and You desire to accep

Convertible Bond Subscription Agreement, dated May 3, 2023, among Cyworld Z Co., Ltd. and Exicure, Inc.

Exhibit 10.4 Cyworld Z Co., Ltd. 13th Bearer’s Non-Guaranteed Private Placement Convertible Bonds With Coupons Convertible Bond Subscription Agreement Total Issue Amount : USD 1,000,000 Subscription Agreement Execution Date: [5/03], 2023 Payment Date and Issue Date: [5/03], 2023 1 Convertible Bond Subscription Agreement This Convertible Bond Subscription Agreement (the “Agreement”) is made and ent

Separation and Release Agreement, dated May 27, 2023, among Exicure, Inc. and Sarah Longoria.

Exhibit 10.6 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) by and between Exicure, Inc. (the “Company”) and Sarah Longoria (“You” or “Your”) (the Company and You collectively referred to as the “Parties”), is entered into and effective as of May 26, 2023 (the “Effective Date”). WHEREAS, You have been employed by the Company on an at-will basis; WHEREAS, t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39011 EXI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 (August 4, 2023) E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 (August 4, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Comm

US30205M2008 / Exicure Inc / CBI USA, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 10) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M200 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. and DGP Co., Ltd. c/o Baker & Hostetler LLP One North Wacker Drive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 (August 1, 2023) E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 (August 1, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Comm

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Exhibit 99.1 Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update CHICAGO, IL. — July 14, 2022 — Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, susp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39011 EX

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 EXICURE, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Number

Assignment of Rights Agreement

EX-99.2 Exhibit 99.2 ASSIGNMENT OF RIGHTS This Assignment (this “Assignment”) is made and entered into this 23rd day of June, 2023, by and between CBI USA, Inc., a Delaware corporation (“Assignor”), and DGP Co., Ltd., a corporation organized under the Laws of Korea, formerly known as Daehan Green Power Corporation (“Assignee”). WHEREAS, Assignor is a party to that certain Securities Purchase Agree

US30205M2008 / Exicure Inc / CBI USA, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 9) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M200 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. and DGP Co., Ltd. c/o Baker & Hostetler LLP One North Wacker Drive,

Joint Filing Agreement of the Reporting Persons

EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of the Common Stock of the Company and further agree that this Joint Filing Agreement be included as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 (June 12, 2023) Exi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 (June 12, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commis

First Amendment to the Separation and Release Agreement of Matthias Schroff, dated June

Exhibit 10.1 FIRST AMENDMENT TO THE SEPARATION & RELEASE AGREEMENT OF MATTHIAS SCHROFF This First Amendment To The Separation & Release Agreement Of Matthias Schroff (the “Amendment”) is effective as of the 12th day of June, 2023 (the “Effective Date”), by and between Matthias Schroff (the former “Executive”) and EXICURE, INC. (the “Company”) (each of the former Executive and the Company, a “Party

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 (June 5, 2023) Exicu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 (June 5, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 (May 24, 2023) Exicu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 (May 24, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commissi

Separation and Release Agreement

Exhibit 10.1 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) by and between Exicure, Inc. (the “Company”) and Sarah Longoria (“You” or “Your”) (the Company and You collectively referred to as the “Parties”), is entered into and effective as of May 26, 2023 (the “Effective Date”). WHEREAS, You have been employed by the Company on an at-will basis; WHEREAS, t

Amended and Restated Employment Agreement

Exhibit 10.2 Amended and Restated Employment Agreement This Employment Agreement (the “Agreement”) between Exicure, Inc., a Delaware corporation (the “Company”), and Joshua Miller (“Executive”) (each of Executive and the Company, a “Party,” and collectively, the “Parties”), is entered into as of May 9, 2023. Whereas, Executive and the Company are parties to that certain Employment Agreement, dated

1

Exhibit 10.3 May 5, 2023 Joshua Miller Re: Retention Agreement Dear Josh: Thank you for all of your contributions to Exicure, Inc. (the “Company”). Your role is key to our success and we are excited to offer you the retention award described below pursuant to the terms and conditions set forth in this agreement (this “Retention Agreement”). This Retention Agreement will be effective as of May 5, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 Exicure, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Number)

1

Exhibit 99.1 Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives 5/26/2023 CHICAGO-(BUSINESS WIRE)-Exicure, Inc. (Nasdaq: XCUR), (“Exicure” or the “Company”), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 (May 17, 2023) Exicu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 (May 17, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commissi

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exhibit 99.1 Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q CHICAGO, IL. — May 19, 2023 — Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on May 17, 2023 notifying the Company that, as a result of the Company’s failure to timely file its Quarterly Report on Fo

Convertible Bond Subscription Agreement, dated May 16, 2023, among Cyworld Z Co., Ltd. and Exicure, Inc.

Exhibit 10.1 Cyworld Z Co., Ltd. 14th Bearer’s Non-Guaranteed Private Placement Convertible Bonds With Coupons Convertible Bond Subscription Agreement Total Issue Amount : USD 1,000,000 Subscription Agreement Execution Date: [5/16], 2023 Payment Date and Issue Date: [5/16], 2023 1 Convertible Bond Subscription Agreement This Convertible Bond Subscription Agreement (the “Agreement”) is made and ent

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 (May 16, 2023) Exicu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 (May 16, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commissi

US30205M2008 / Exicure Inc / CBI USA, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 8) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M200 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. c/o Baker & Hostetler LLP One North Wacker Drive, Suite 4500 Chicag

2

EX-99.2 Exhibit 2 May 15, 2023 Exicure, Inc. 2430 N Halsted St Chicago, IL 60614 Dear Members of the Board: We are writing to you on behalf of CBI USA, Inc. and CBI Co., Ltd. (together, “CBI” or “we”), which have invested over $10 million in Exicure, Inc. (the “Company” or “Exicure”), making us the Company’s largest shareholder owning over 50% of all outstanding shares. The past several weeks have

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39011 CUSIP NUMBER 30205M200

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39011 CUSIP NUMBER 30205M200 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR ☐ For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 (May 8, 2023) Exicur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 (May 8, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commissio

Letter from KPMG LLP, dated May 11, 2023

Exhibit 16.1 May 11, 2023 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Exicure, Inc. and subsidiary (the “Company”) and, under the date of March 27, 2023, we reported on the consolidated financial statements of the Company as of and for the years ended December 31, 2022 and 2021. On May 8, 2023, we resigned. We have re

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 (May 3, 2023) Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission

Convertible Bond Subscription Agreement, dated May 3, 2023, among Cyworld Z Co., Ltd. and Exicure, Inc.

Exhibit 10.1 Cyworld Z Co., Ltd. 13th Bearer’s Non-Guaranteed Private Placement Convertible Bonds With Coupons Convertible Bond Subscription Agreement Total Issue Amount : USD 1,000,000 Subscription Agreement Execution Date: [5/03], 2023 Payment Date and Issue Date: [5/03], 2023 1 Convertible Bond Subscription Agreement This Convertible Bond Subscription Agreement (the “Agreement”) is made and ent

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Exhibit 99.1 Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld CHICAGO, IL. — May 4, 2023 — Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that it has invested in Cyworld Z Co. Ltd. ("Cyworld Z"), the operator of a Korean SNS platform "

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Exicure, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 Exicure, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Separation and Release Agreement, dated April 26, 2023, among Exicure, Inc. and Matthias Schroff

Exhibit 10.2 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) by and between Exicure, Inc. (the “Company”) and Matthias Schroff (“You” or “Your”) (the Company and You collectively referred to as the “Parties”), is entered into and effective as of April 26, 2023 (the “Effective Date”). WHEREAS, You have been employed by the Company on an at-will basis; WHEREA

dated April 26, 2023, among Exicure, Inc. and Elias Papadimas

EX-10.3 4 ex103-papadimassragmt.htm EX-10.3 Exhibit 10.3 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) by and between Exicure, Inc. (the “Company”) and Elias Papadimas (“You” or “Your”) (the Company and You collectively referred to as the “Parties”), is entered into and effective as of April 26, 2023 (the “Effective Date”). WHEREAS, You have been employed

Employment Agreement, dated April 27, 2023, among Exicure, Inc. and Jung S. Kim

Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), by and among Exicure, Inc. (the “Company”) and Jung S. Kim (“You” or “Your”) (the Company and You each a “Party”, and collectively the “Parties”), is entered into and effective as of April 27, 2023 (the “Effective Date”).1 WHEREAS, the Company desires to employ You as its Chief Executive Officer, and You desire to accep

Memorandum of Understanding*

EX-1 Exhibit 1 Memorandum of Understanding Article 1 (Purpose of Memorandum of Understanding) This Memorandum of Understanding (this “MOU”) is for the sale of shares issued by EXICURE INC [NASDAQ: XCUR] (the “Target Company”) owned by CBI USA INC (the “Transferer”) to HNB Design Co.

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 31.1.1 CERTIFICATIONS I, Jung Sang Kim, certify that: 1. I have reviewed this Annual Report on Form 10-K/A of Exicure, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to

US30205M2008 / Exicure Inc / CBI USA, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 7) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M200 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. 3000 Western Avenue #400 Seattle, WA 98121 (425) 220-2542 With copy

Second Amendment to Employment Agreement by and between Exicure, Inc. and Sarah Longoria, dated September 23, 2022

Exhibit 10.16 SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT OF SARAH LONGORIA This Second Amendment To The Employment Agreement Of Sarah Longoria (the “Amendment”) is effective as of the 23rd day of September, 2022 (the “Effective Date”), by and between Sarah Longoria (the “Executive”) and EXICURE, INC. (the “Company”) (each of the Executive and the Company, a “Party,” and collectively, the “Partie

Subsidiaries of Exicure, Inc.

Exhibit 21.1 Subsidiaries of Exicure, Inc. Name: Jurisdiction of Organization: Exicure Operating Company Delaware

First Amendment to Employment Agreement by and between Exicure, Inc. and Sarah Longoria, dated December 10, 2021

Exhibit 10.15 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF SARAH LONGORIA This FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF SARAH LONGORIA (the “Amendment”) is effective as of the 10th day of December 2021 (the “Effective Date”), by and between SARAH LONGORIA (the “Executive”) and EXICURE, INC. (the “Company”) (each of the Executive and the Company, a “Party,” and collectively, the “Parties”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi

Employment Agreement by and between Exicure, Inc. and Sarah Longoria, dated March 5, 2021

Exhibit 10.14 Employment Agreement This Employment Agreement (the “Agreement”) between Exicure, Inc., a Delaware corporation (the “Company”), and Sarah Longoria (the “Executive”) (each of the Executive and the Company, a “Party,” and collectively, the “Parties”), is entered into as of March 5th, 2021. Whereas, the Executive desires to be employed by the Company as “Vice President of Human Resource

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Exhibit 99.1 Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors CHICAGO, IL. — April 27, 2023 — Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of April 26, 2023, Jung-Sang (Michael) Kim was appoi

US30205M2008 / Exicure Inc / Carlyle Group Inc. - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Exicure, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 (Name, Addre

Subsidiaries of Exicure, Inc.

Exhibit 21.1 Subsidiaries of Exicure, Inc. Name: Jurisdiction of Organization: Exicure Operating Company Delaware

First Amendment to Employment Agreement by and between Exicure, Inc. and Sarah Longoria, dated December 10, 2021

Exhibit 10.15 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF SARAH LONGORIA This FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF SARAH LONGORIA (the “Amendment”) is effective as of the 10th day of December 2021 (the “Effective Date”), by and between SARAH LONGORIA (the “Executive”) and EXICURE, INC. (the “Company”) (each of the Executive and the Company, a “Party,” and collectively, the “Parties”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 Exicure, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39011

Employment Agreement by and between Exicure, Inc. and Sarah Longoria, dated March 5, 2021

Exhibit 10.14 Employment Agreement This Employment Agreement (the “Agreement”) between Exicure, Inc., a Delaware corporation (the “Company”), and Sarah Longoria (the “Executive”) (each of the Executive and the Company, a “Party,” and collectively, the “Parties”), is entered into as of March 5th, 2021. Whereas, the Executive desires to be employed by the Company as “Vice President of Human Resource

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Exhibit 99.1 Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update CHICAGO, IL. — March 27, 2023 — Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the year ended December 31, 2022 and provided an updat

Second Amendment to Employment Agreement by and between Exicure, Inc. and Sarah Longoria, dated September 23, 2022

EX-10.16 4 exicureexhibit1016-123122.htm EX-10.16 Exhibit 10.16 SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT OF SARAH LONGORIA This Second Amendment To The Employment Agreement Of Sarah Longoria (the “Amendment”) is effective as of the 23rd day of September, 2022 (the “Effective Date”), by and between Sarah Longoria (the “Executive”) and EXICURE, INC. (the “Company”) (each of the Executive and the

CBI USA, Inc. 교환사채 인수계약서 Exchangeable Bond Purchase Agreement CBI USA, Inc. 대한그린파워 주식회사 Daehan Green Power Corporation 2023. 2. 22.

EX-1 Exhibit 1 CBI USA, Inc. 교환사채 인수계약서 Exchangeable Bond Purchase Agreement 발행회사 Issuer CBI USA, Inc. 인수인 Subscriber 대한그린파워 주식회사 Daehan Green Power Corporation 2023. 2. 22. 교환사채 인수계약서 Exchangeable Bond Purchase Agreement CBI USA, Inc.(이하 “발행회사”라 한다)는 2023년 2월 22일에 개최한 이사회 결의에 의거하여 2023년 2월 22일 발행하는 제1회 무기명식 이권부 무보증 사모 교환사채(이하 “본 사채”라 한다)에 관하여 대한그린파워 주식회사(이하 “인수인” 또는 “사채권자”라 한다)를 인수인으로 하며 아래와 같이 인

XCUR / Exicure Inc / CBI USA, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M101 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. 3000 Western Avenue #400 Seattle, WA 98121 (425) 220-2542 With copy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 Exicure, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Exicure, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Exicure, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Nu

US30205M2008 / Exicure Inc / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

XCUR / Exicure Inc / CBI USA, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M101 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. 3000 Western Avenue #400 Seattle, WA 98121 (425) 220-2542 With copy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 Exicure, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Num

XCUR / Exicure Inc / CARLSON CAPITAL L P - SC 13G/A Passive Investment

SC 13G/A 1 d446996dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Exicure, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 30205M101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the ap

XCUR / Exicure Inc / CBI USA, Inc. - SC 13D/A Activist Investment

SC 13D/A 1 d453148dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M101 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. 3000 Western Avenue #400 Seattle, WA

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2023 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Num

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Nu

XCUR / Exicure Inc / CBI USA, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M101 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. 3000 Western Avenue #400 Seattle, WA 98121 (425) 220-2542 With copy

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Exicure, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Mutual Termination Agreement, dated December 12, 2022, by and between Exicure, Inc. and Ipsen Biopharm Limited.

Exhibit 10.1 Mutual Termination Agreement for Collaboration, Option and License Agreement (the ?Collaboration Agreement?) between Exicure, Inc. (?Exicure?) and Ipsen Biopharm Limited (?Ipsen?) THIS MUTUAL TERMINATION AGREEMENT (?Mutual Termination Agreement?) is made and entered into as of December 12th, 2022 (the ?Termination Effective Date?) between EXICURE, INC., a corporation organized and exi

Letter Agreement, dated December 13, 2022, by and between Exicure, Inc. and Allergan Pharmaceuticals International Limited.

Exhibit 10.2 Allergan Pharmaceuticals International Limited Clonshaugh Business & Technology Park Dublin 17 D17 E400, Ireland www.allergan.com December 5, 2022 Exicure, Inc. (via certified mail) 8045 Lamon Avenue, Suite 410 Skokie, IL 60077 Attn: CFO Re: The Collaboration, Option and License Agreement between Exicure, Inc. and Allergan Pharmaceuticals International Limited To Whom It May Concern:

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements –Exicure and AbbVie have terminated their agreement relating to the development programs targeting hair loss disorders –Exicure and Ipsen have terminated their agreement

Exhibit 99.1 Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements ?Exicure and AbbVie have terminated their agreement relating to the development programs targeting hair loss disorders ?Exicure and Ipsen have terminated their agreement relating to the development programs targeting Angelman syndrome and Huntington?s disease CHICAGO, IL. ? December 14, 2022 ? Exicure, In

Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Nu

XCUR / Exicure Inc / CARLSON CAPITAL L P - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Exicure, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 30205M101 (CUSIP Number) December 1, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rul

JOINT FILING AGREEMENT

EXHIBIT I JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Exicure, Inc.

XCUR / Exicure Inc / CBI USA, Inc. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M101 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. 3000 Western Avenue #400 Seattle, WA 98121 (425) 220-2542 With copy to: John

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3901

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Exhibit 99.1 Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update CHICAGO, IL. ? November 14, 2022 ? Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the quarter ended September 30, 2022 and provid

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of

Amendment Six to the Amended Restated License Agreement between Exicure OpCo and Northwestern University dated as of October 10, 2022.

Exhibit 10.5 SIXTH AMENDMENT TO THE LICENSE AGREEMENT BY AND BETWEEN NORTHWESTERN UNIVERSITY AND EXICURE OPERATING COMPANY. This SIXTH AMENDMENT (“Amendment”), effective as of October 10, 2022 (the “Sixth Amendment Effective Date”), is entered into by and between NORTHWESTERN UNIVERSITY, an Illinois not-for-profit corporation having a principal office located at 633 Clark Street, Evanston, Illinoi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

XCUR / Exicure Inc / CBI USA, Inc. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) EXICURE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30205M101 (CUSIP Number) Kyungwon Oh Chief Executive Officer CBI USA, Inc. 3000 Western Avenue #400 Seattle, WA 98121 (425) 220-2542 With copy to: John

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Exicure, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Exicure, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Side Letter to Securities Purchase Agreement, dated as of October 31, 2022 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on October 31, 2022).

Exhibit 10.1 October 31, 2022 Exicure, Inc. 2430 N. Halsted St. Chicago, IL 60614 Re: Securities Purchase Agreement To Whom It May Concern: Reference is made to the Securities Purchase Agreement (the ?Agreement?), dated as of September 26, 2022, by and between Exicure, Inc. (the ?Company?) and CBI USA, Inc. (the ?Purchaser?). Capitalized terms used and not otherwise defined herein shall have the m

Exicure, Inc. Enters into Definitive Agreement with CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Exhibit 99.1 Exicure, Inc. Enters into Definitive Agreement with CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives ?Upon satisfaction of certain closing conditions including approval by Exicure stockholders, existing investor CBI USA, Inc. will purchase an aggregate of 3,400,000 shares of comm

Second Amendment to the Amended and Restated Employment Agreement, by and between Exicure, Inc. and Elias Papadimas, dated September 23, 2022.

Exhibit 10.4 SECOND AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT OF ELIAS D. PAPADIMAS This Second Amendment To The Amended And Restated Employment Agreement Of Elias D. Papadimas (this ?Amendment?) is effective as of this 23rd day of September, 2022 (the ?Effective Date?), by and between ELIAS D. PAPADIMAS (the ?Executive?) and EXICURE, INC. (the ?Company?) (each of the Executive an

First Amendment to the Second Amended and Restated Employment Agreement, by and between Exicure, Inc. and Matthias Schroff, dated September 23, 2022.

Exhibit 10.3 FIRST AMENDMENT TO THE SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT OF MATTHIAS SCHROFF This First Amendment To The Second Amended And Restated Employment Agreement Of Matthias Schroff (the ?Amendment?) is effective as of this 23rd day of September, 2022 (the ?Effective Date?), by and between MATTHIAS SCHROFF (the ?Executive?) and EXICURE, INC. (the ?Company?) (each of the Executi

Securities Purchase Agreement, dated September 26, 2022, by and between Exicure, Inc. and CBI USA.

Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of September 26, 2022, by and among Exicure, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on Schedule 1 hereto (each, including its successors and assigns, a ?Purchaser? and together, the ?Purchasers?). Capitalized terms used herein but not othe

Registration Rights Agreement, dated September 26, 2022, by and between Exicure, Inc. and CBI USA.

Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of September 26, 2022, by and among Exicure, Inc., a Delaware corporation (the ?Company?), and each purchasers identified on Schedule 1 hereto (each, including its successors and assigns, a ?Purchaser? and together, the ?Purchasers?), and shall become effec

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2022 EXICURE, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39011 81-5333008 (State or other jurisdiction of incorporation) (Commission File N